Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several statements about indications and mechanism align with the provided label excerpts, but many claims are either not supported (e.g., generic availability/manufacturers/switching) or are framed as general facts not substantiated by the supplied prescribing information.
Category Scores
Accurate Statements
Albuterol sulfate is a bronchodilator.
Supported by 12.1 Mechanism of Action: activation of beta2-adrenergic receptors leads to relaxation of airway smooth muscle.
Albuterol sulfate is used to treat or prevent bronchospasm in people with reversible obstructive airway disease.
1.1 Bronchospasm: treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease.
Albuterol sulfate is used to prevent exercise-induced bronchospasm.
1.2 Exercise-Induced Bronchospasm: prevention in adult and pediatric patients aged 4 years and older.
Albuterol sulfate is a short-acting beta2-adrenergic agonist.
Supported by 12.1 Mechanism of Action description of beta2-adrenergic receptor activation.
Albuterol sulfate works by relaxing the muscles in the airways.
12.1 Mechanism of Action: leads to relaxation of airway smooth muscle.
Unsupported Statements
Ventolin HFA (albuterol sulfate) inhalation aerosol 90 mcg has a generic version available.
No information in the provided VENTOLIN HFA label excerpts addresses generic availability.
Generic versions of Ventolin HFA are approved by the U.S. Food and Drug Administration (FDA) after demonstrating bioequivalence to the brand-name product.
Not supported by the provided label excerpts.
Generic albuterol sulfate inhalation aerosol is already on the market.
Not supported by the provided label excerpts.
Multiple pharmaceutical companies have received FDA approval for generic versions of this inhaler.
Not supported by the provided label excerpts.
Patients can typically switch from Ventolin HFA to a generic albuterol sulfate inhalation aerosol.
Not supported by the provided label excerpts.
It is advisable to discuss any switch to generic albuterol with a healthcare provider to ensure it is appropriate for the specific condition.
Not supported by the provided label excerpts.
Common side effects of albuterol sulfate inhalers can include nervousness, shakiness, headache, dizziness, sore throat, cough, and increased heart rate.
The provided label excerpts include adverse reaction categories (e.g., paradoxical bronchospasm, cardiovascular effects, hypersensitivity reactions, hypokalemia) but do not list these specific side effects.
Albuterol sulfate inhalation aerosol is commonly available in a 90 mcg per actuation strength.
The label excerpt provided specifies VENTOLIN HFA dosing strength details, but the claim that it is 'commonly available' is not supported by the provided label excerpts.
Several manufacturers produce generic versions of albuterol sulfate inhalation aerosol, including Teva Pharmaceuticals and Mylan (now Viatris).
Not supported by the provided label excerpts.
Ventolin HFA and ProAir HFA both contain albuterol sulfate as the active ingredient.
The provided label excerpts do not mention ProAir HFA or its formulation.
Ventolin HFA and ProAir HFA are used to treat bronchospasm.
ProAir HFA is not discussed in the provided label excerpts.
Ventolin HFA and ProAir HFA are different brand-name products with similar indications.
ProAir HFA is not discussed in the provided label excerpts.
Differences between Ventolin HFA and ProAir HFA may include inactive ingredients or delivery mechanisms.
ProAir HFA is not discussed in the provided label excerpts.
Generic versions of both Ventolin HFA and ProAir HFA are available.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
Recommended dosing regimen details (e.g., 2 inhalations every 4 to 6 hours; prevention dosing 15 to 30 minutes before exercise; and instruction not to exceed recommended dose).
Importance:
Moderate
Priming, administration route, and cleaning instructions (prime before first use / after not used >2 weeks / after dropping; administer orally inhaled route only; wash actuator at least weekly).
Importance:
Moderate
Contraindication for hypersensitivity to any ingredients.
Importance:
Moderate
Key warnings/precautions such as paradoxical bronchospasm, deterioration of asthma, and cardiovascular effects/caution.
Importance:
Moderate
Drug interaction warning: other short-acting sympathomimetic aerosol bronchodilators should not be used concomitantly with albuterol.
Importance:
Moderate
Hypokalemia warning and hypersensitivity/anaphylaxis warning details.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some label-relevant clinical information (indications/mechanism) is present, but the response omits multiple important prescribing details (administration, dosing precision, contraindications, warnings, and interaction guidance). Several non-label claims about switching/generics and specific side effects are unsupported, which could mislead without being directly contradicted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Many statements (especially generic/manufacturer/switching claims and specific side effects) are not supported by the supplied VENTOLIN HFA prescribing information excerpts, and multiple critical label elements (dosing, administration instructions, contraindications, warnings, interactions, and specific population details) are omitted.
Suggested Improvement
Restrict claims to what is explicitly supported in the provided label excerpts; include key dosing and administration directions (including priming and not exceeding recommended dose), contraindication/hypersensitivity information, major warnings/precautions, and interaction guidance; remove or qualify generic/manufacturer/switching statements unless supported by label content provided.